Related references
Note: Only part of the references are listed.Review: Leishmaniasis in the United States: Treatment in 2012
Henry W. Murray
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2012)
Characterization and identification of suspected counterfeit miltefosine capsules
Thomas P. C. Dorlo et al.
ANALYST (2012)
Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis
Thomas P. C. Dorlo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Miltefosine induces metacaspase and PARP genes expression in Leishmania infantum
Shahram Khademvatan et al.
Brazilian Journal of Infectious Diseases (2012)
Noninferiority of Miltefosine Versus Meglumine Antimoniate for Cutaneous Leishmaniasis in Children
Luisa Consuelo Rubiano et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters
Zubeyde Akin Polat et al.
PARASITOLOGY RESEARCH (2012)
Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms
Humberto Goncalves Bertao et al.
PARASITOLOGY RESEARCH (2012)
Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis
Hannah E. Cummings et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal
Thomas P. C. Dorlo et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Multiple Mutations in Heterogeneous Miltefosine-Resistant Leishmania major Population as Determined by Whole Genome Sequencing
Adriano C. Coelho et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Leishmania Resistance to Miltefosine Associated with Genetic Marker
Sandrine Cojean et al.
EMERGING INFECTIOUS DISEASES (2012)
Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asia
Michael O. Harhay et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil
Anette Chrusciak-Talhari et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh
Mahmudur Rahman et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality
E. Sinkala et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2011)
Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis
V. Ramesh et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Miltefosine, a promising novel agent for schistosomiasis mansoni
Maha M. Eissa et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2011)
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
Shyam Sundar et al.
LANCET (2011)
Miltefosine Induces Apoptosis-Like Cell Death in Yeast via Cox9p in Cytochrome c Oxidase
Xiaoming Zuo et al.
MOLECULAR PHARMACOLOGY (2011)
Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes
Fernanda de Aquino Marinho et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2011)
Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
Tansy Edwards et al.
TRIALS (2011)
Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
Raymond Omollo et al.
TRIALS (2011)
Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania
W. Moreira et al.
CELL DEATH & DISEASE (2011)
Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
Thomas P. C. Dorlo et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis
Ivan Velez et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2010)
Miltefosine Efficiently Eliminates Leishmania major Amastigotes from Infected Murine Dendritic Cells without Altering Their Immune Functions
Klaus Griewank et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial
K. Hartmann et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Miltefosine Treatment of Leishmania major Infection: An Observational Study Involving Dutch Military Personnel Returning from Northern Afghanistan
P. P. A. M. van Thiel et al.
CLINICAL INFECTIOUS DISEASES (2010)
Designing and Reporting Clinical Trials on Treatments for Cutaneous Leishmaniasis
Urba Gonzalez et al.
CLINICAL INFECTIOUS DISEASES (2010)
Oral miltefosine in post-kala-azar dermal leishmaniasis - experience in three cases
Sujay Khandpur et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2010)
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent
Karin Seifert et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Quantification of CLR1401, a novel alkylphosphocholine anticancer agent, in rat plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection
Hongliang Jiang et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2010)
Combination therapy for visceral leishmaniasis
Johan van Griensven et al.
LANCET INFECTIOUS DISEASES (2010)
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Shyam Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting the PI3K/Akt Cell Survival Pathway to Induce Cell Death of HIV-1 Infected Macrophages with Alkylphospholipid Compounds
Amanda Lucas et al.
PLOS ONE (2010)
Disruption of the Lipid-Transporting LdMT-LdRos3 Complex in Leishmania donovani Affects Membrane Lipid Asymmetry but Not Host Cell Invasion
Adrien Weingaertner et al.
PLOS ONE (2010)
Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
Ahmed M. Musa et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
Asrat Hailu et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent
Filip Meheus et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial
Paulo R. Machado et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania braziliensis Refractory to the Drug
Maria P. Sanchez-Canete et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences
Marieke Vermeersch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In Vitro Sensitivity Testing of Leishmania Clinical Field Isolates: Preconditioning of Promastigotes Enhances Infectivity for Macrophage Host Cells
Raquel Inocencio da Luz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Anti-Acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent
Julia Walochnik et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Miltefosine Promotes IFN-gamma-Dominated Anti-Leishmanial Immune Response
Pallavi Wadhone et al.
JOURNAL OF IMMUNOLOGY (2009)
The p110δ Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to Leishmania major by Regulating Expansion and Tissue Homing of Regulatory T Cells
Dong Liu et al.
JOURNAL OF IMMUNOLOGY (2009)
Administration of Miltefosine and Meglumine Antimoniate in Healthy Dogs: Clinicopathological Evaluation of the Impact on the Kidneys
Paolo Bianciardi et al.
TOXICOLOGIC PATHOLOGY (2009)
Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases
T. A. Patel et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2009)
Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India
Piero Olliaro et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2009)
Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum
M. Shahiduzzaman et al.
VETERINARY PARASITOLOGY (2009)
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients
Thomas P. C. Dorlo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement
Esther Castanys-Munoz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine
Shyam Sundar et al.
CLINICAL INFECTIOUS DISEASES (2008)
Anticancer alkylphospholipids: Mechanisms of action, cellular sensitivity and resistance, and clinical prospects
Wim J. van Blitterswijk et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells
Maria P. Carrasco et al.
FEBS JOURNAL (2008)
Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine)
Krittalak Chakrabandhu et al.
FEBS LETTERS (2008)
In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains
L. Huelves et al.
JOURNAL OF CHEMOTHERAPY (2008)
Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard
Lars H. Lindner et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry
Thomas P. C. Dorlo et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy
Pauline Chugh et al.
RETROVIROLOGY (2008)
Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal - the challenges for diagnosis and treatment
Shyam Sundar et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2008)
Pentamidine Dosage: A Base/Salt Confusion
Thomas P. C. Dorlo et al.
PLOS NEGLECTED TROPICAL DISEASES (2008)
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo
Karin Seifert et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis
Sujit Kumar Bhattacharya et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Synthesis, antifungal and antimicrobial activity of alkylphospholipids
Daniel Obando et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran
M. Mohebali et al.
ACTA TROPICA (2007)
A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids
Esther Castanys-Munoz et al.
MOLECULAR MICROBIOLOGY (2007)
In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci
Daniel Llull et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes
Juan Roman Luque-Ortega et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Miltefosine afects lipid metabolism in Leishmania donovani promastigotes
M. Rakotomanga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process
Cecile Menez et al.
LIPIDS (2007)
Intestinal absorption of miltefosine:: Contribution of passive paracellular transport
Cecile Menez et al.
PHARMACEUTICAL RESEARCH (2007)
Drug policy for visceral leishmaniasis: a cost-effectiveness analysis
V. Vanlerberghe et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2007)
Treatment of Bolivian mucosal leishmaniasis with miltefosine
J. Soto et al.
CLINICAL INFECTIOUS DISEASES (2007)
Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses
O. Zerpa et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes
Zhongsheng Tong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Development of miltefosine as an oral treatment for leishmaniasis
H. Sindermann et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2006)
Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA
P. J. de Vries et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2006)
Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives
Simon L. Croft et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2006)
Liposomal amphotericin B for the treatment of visceral leishmaniasis
Caryn Bern et al.
CLINICAL INFECTIOUS DISEASES (2006)
Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to miltefosine by inhibiting drug efflux
Jose M. Perez-Victoria et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites
F. Javier Perez-Victoria et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection
K Ritmeijer et al.
CLINICAL INFECTIOUS DISEASES (2006)
Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine
Shyam Sundar et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2006)
Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy
AD Belay et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2006)
Modulation of intestinal barrier properties by miltefosine
C Menez et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Hexadecylphosphocholine (Miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis
F Widmer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis
C Blaha et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
K Seifert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions
M Rakotomanga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2deoxy-D-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells
T Márián et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes
C Paris et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India
SK Bhattacharya et al.
CLINICAL INFECTIOUS DISEASES (2004)
Possible mechanism of miltefosine-mediated death of Leishmania donovani
NK Verma et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis
RM Santa-Rita et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Miltefosine for New World cutaneous leishmaniasis
J Soto et al.
CLINICAL INFECTIOUS DISEASES (2004)
Functional cloning of the miltefosine transporter -: A novel P-type phospholipid translocase from Leishmania involved in drug resistance
FJ Pérez-Victoria et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major
R Zufferey et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)
K Seifert et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2003)
Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug
FJ Pérez-Victoria et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway
GA Ruiter et al.
ANTI-CANCER DRUGS (2003)
Antiprotozoal activities of phospholipid analogues
SL Croft et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2003)
Oral miltefosine for Indian visceral leishmaniasis
S Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs
R Zufferey et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2002)
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi
VB Saraiva et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis
AH van der Luit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B
P Escobar et al.
ACTA TROPICA (2002)
Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.
J Walochnik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Monitoring drug resistance in leishmaniasis
SL Croft
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2001)
Alkyl-lysophospholipid resistance in multi drug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator
JM Pérez-Victoria et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry
EW Woo et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2001)
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice
P Escobar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
MDR1 causes resistance to the antitumour drug miltefosine
M Rybczynska et al.
BRITISH JOURNAL OF CANCER (2001)
Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica
K Seifert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi:: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole
R Lira et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients
CH Smorenburg et al.
ANTI-CANCER DRUGS (2000)
Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania
H Lux et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2000)
Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi
RM Santa-Rita et al.
ACTA TROPICA (2000)
Share Paper
